MDMB-4en-피나카

MDMB-4en-PINACA
MDMB-4en-피나카
MDMB-4en-PINACA.svg
법적현황
법적현황
식별자
  • 메틸(S)-3-3-디메틸-2-(1-(펜트-4-en-1-yl)-1H-indazole-3-카르복사미도)부탄산염
CAS 번호
  • 2504100-70-1 checkY
켐스파이더
유니
화학 및 물리적 데이터
공식C20H27N3O3
어금질량357.454 g·190−1
3D 모델(JSmol)
  • O=C(N[C@H](C)(C)C(C)C(OC)=O)C1=NN(CCC=C)2=C1C=CC=C2.
  • InChI=1S/C20H27N3O3/c1-6-7-10-13-23-15-12-9-8-11-14(15)16(22-23)18(24)21-17(19(25)26-5)20(2,3)4/h6,8-9,11-12,17H,1,7,10,13H2,2-5H3,(H,21,24)/t17-/m1/s1
  • 키:LWOCBHBBWNGPGM-QGZVFWFLSA-N

MDMB-4en-PINACA(또한 잘못 알려진 5-CL-ADB-A)는 인다졸 기반의 합성 카나비노이드로, 온라인에서 디자이너 약품으로 판매되어 왔다.[1][2][3] MDMB-4en-PINACA는 5-fluoropentyl를 펜트-4-ene moiety(4-en)로 교체하기 때문에 5F-MDB-PINAACA와 다르다.[4]

EC50 값이 2.47nM인 CB1 수용체의 강력한 작용제 역할을 한다.[5][6][7][8]

법적현황

스웨덴 보건청은 2019년 12월 18일 MDMB-4en-PINACA를 위험 물질로 분류할 것을 제안했다.[9]

참고 항목

참조

  1. ^ Watanabe S, Vikingsson S, Åstrand A, Gréen H, Kronstrand R (December 2019). "Biotransformation of the New Synthetic Cannabinoid with an Alkene, MDMB-4en-PINACA, by Human Hepatocytes, Human Liver Microsomes, and Human Urine and Blood". The AAPS Journal. 22 (1): 13. doi:10.1208/s12248-019-0381-3. PMID 31848852. S2CID 209393242.
  2. ^ "MDMB-4en-PINACA". www.caymanchem.com.
  3. ^ Erol Ozturk Y, Yeter O (January 2021). "In Vitro Phase I Metabolism of the Recently Emerged Synthetic MDMB-4en-PINACA and Its Detection in Human Urine Samples". Journal of Analytical Toxicology. 44 (9): 976–984. doi:10.1093/jat/bkaa017. PMID 32091101.
  4. ^ "ANALYTICAL REPORT MDMB-PINACA N1-pentyl-4-en isomer" (PDF). www.policija.si.
  5. ^ Krotulski AJ, Cannaert A, Stove C, Logan BK (February 2021). "The next generation of synthetic cannabinoids: Detection, activity, and potential toxicity of pent-4en and but-3en analogues including MDMB-4en-PINACA". Drug Testing and Analysis. 13 (2): 427–438. doi:10.1002/dta.2935. PMID 32997377.
  6. ^ Cannaert A, Sparkes E, Pike E, Luo JL, Fang A, Kevin RC, et al. (December 2020). "Synthesis and in Vitro Cannabinoid Receptor 1 Activity of Recently Detected Synthetic Cannabinoids 4F-MDMB-BICA, 5F-MPP-PICA, MMB-4en-PICA, CUMYL-CBMICA, ADB-BINACA, APP-BINACA, 4F-MDMB-BINACA, MDMB-4en-PINACA, A-CHMINACA, 5F-AB-P7AICA, 5F-MDMB-P7AICA, and 5F-AP7AICA". ACS Chemical Neuroscience. 11 (24): 4434–4446. doi:10.1021/acschemneuro.0c00644. PMID 33253529.
  7. ^ Pike E, Grafinger KE, Cannaert A, Ametovski A, Luo JL, Sparkes E, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays: Part I-Synthesis, analytical characterization, and binding affinity for human CB1 receptors". Drug Testing and Analysis. 13 (7): 1383–1401. doi:10.1002/dta.3037. PMID 33787091.
  8. ^ Grafinger KE, Cannaert A, Ametovski A, Sparkes E, Cairns E, Banister SD, et al. (July 2021). "Systematic evaluation of a panel of 30 synthetic cannabinoid receptor agonists structurally related to MMB-4en-PICA, MDMB-4en-PINACA, ADB-4en-PINACA, and MMB-4CN-BUTINACA using a combination of binding and different CB1 receptor activation assays-Part II: Structure activity relationship assessment via a β-arrestin recruitment assay". Drug Testing and Analysis. 13 (7): 1402–1411. doi:10.1002/dta.3035. PMID 33769699.
  9. ^ "Tjugotre ämnen föreslås klassas som narkotika eller hälsofarlig vara" (in Swedish). Folkhälsomyndigheten. 18 December 2019.